RESEARCH TRIANGLE PARK, NORTH CAROLINA--(MARKET WIRE)--Jun 3, 2007 -- Adherex Technologies Inc. (Toronto:AHX.TO - News)(AMEX:ADH - News), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Phase II clinical data on single-agent ADH-1 and preclinical and preliminary Phase I clinical data on the Company’s product candidate, eniluracil, will be presented today in three poster presentations at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The three studies and key findings are as follows:
